SUPN Stock Price, Chart, Stats & News
Supernus Pharmaceuticals, Inc. (SUPN) is a dividend-paying stock with a current dividend yield of 28.28% as of Nov 10, 2026. It pays $8.13 per share over the trailing twelve months and distributes annually.
SUPN chart
Fundamentals
Gross margin | 85.54% |
Operating margin | -6.19% |
Pretax margin | -6.82% |
Net margin | -5.36% |
Effective tax rate | 21.37% |
ROA | -0.00% |
ROE | -0.01% |
D/E | 0.03x |
Interest coverage ratio | – |
SUPN valuation
P/E | – |
P/S | 3.97x |
P/B | 0.00x |
P/CF | 60.00x |
P/FCF | 62.00x |
P/OCF | 60.00x |
PEG | 0.69x |
EV multiple | 961.73x |
About
Supernus, Inc. is a diversified biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) diseases. Its portfolio of 11 marketed products spans opioid use disorder, psychiatry, and neurology, and includes SUBLOCADE, a long-acting injectable buprenorphine for opioid use disorder, along with sublingual OUD treatments; Qelbree, a non-stimulant treatment for attention-deficit hyperactivity disorder (ADHD); GOCOVRI for dyskinesia in Parkinson’s disease patients receiving levodopa-based therapy; ONAPGO for motor fluctuations in advanced Parkinson’s disease; ZURZUVAE for postpartum depression; and treatments for epilepsy, migraine, cervical dystonia, and chronic sialorrhea, including Oxtellar XR, Trokendi XR, APOKYN, and MYOBLOC. The company also advances a pipeline of novel CNS product candidates.
Related lists
Similar securities
Based on sector and market capitalization
